IL-6 promoter polymorphism in patients with rheumatoid arthritis

被引：58

作者：

Pawlik, A

Wrzesniewska, J

Florczak, M

Gawronska-Szklarz, B

Herczynska, M

机构：

[1] Pomeranian Med Univ, Dept Pharmacokinet & Therapeut Drug Monitoring, PL-70111 Szczecin, Poland

[2] Pomeranian Med Univ, Dept Rheumatol, Szczecin, Poland

来源：

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2005年 / 34卷 / 02期

关键词：

D O I：

10.1080/03009740510026373

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: Rheumatoid arthritis ( RA) is a chronic inflammatory disease in which cytokines play an important role. The aim of the present study was to examine the interleukin-6 (IL-6) 2174 promoter polymorphism in patients with RA and its association with disease susceptibility and activity. Methods: The study included 98 patients with RA diagnosed according to the criteria of the American College of Rheumatology. Polymerase chain reaction (PCR) amplification was used for analysis of the polymorphism at position 2174 in the promoter of the IL-6 gene. Results: The distribution of IL-6 genotypes in RA patients did not differ from that in control subjects. Nevertheless, in patients with a GG genotype the active form of RA was more frequently diagnosed compared with homozygous CC and GC patients. Moreover, in carriers of two G alleles the parameters of disease activity score (DAS28), erythrocyte sedimentation rate (ESR), number of swollen and tender joints] were significantly increased. Conclusion: We suggest that the IL-6 promoter polymorphism may be a genetic risk factor for RA activity.

引用

页码：109 / 113

页数：5

共 28 条

[1] CIRCULATING SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTORS, INTERLEUKIN-2 RECEPTORS, TUMOR-NECROSIS-FACTOR-ALPHA, AND INTERLEUKIN-6 LEVELS IN RHEUMATOID-ARTHRITIS - LONGITUDINAL EVALUATION DURING METHOTREXATE AND AZATHIOPRINE THERAPY [J].

BARRERA, P ;

BOERBOOMS, AMT ;

JANSSEN, EM ;

SAUERWEIN, RW ;

GALLATI, H ;

MULDER, J ;

DEBOO, T ;

DEMACKER, PNM ;

VANDEPUTTE, LBA ;

VANDERMEER, JWM .

ARTHRITIS AND RHEUMATISM, 1993, 36 (08) :1070-1079

[2]

CHOY EH, ARTHRITIS RHEUM, V46, P3143

[3]

CRILLY A, 1995, J RHEUMATOL, V22, P224

[4] Tumor necrosis factor receptor type II (exon 6) and interleukin-6 (-174) gene polymorphisms are not associated with family history but tumor necrosis factor receptor type II is associated with hypertension in patients with rheumatoid arthritis from northern Sweden [J].

Dahlqvist, SR ;

Arlestig, L ;

Sikström, C ;

Linghult, S .

ARTHRITIS AND RHEUMATISM, 2002, 46 (11) :3096-3098

[5] CORRELATION OF SERUM INTERLEUKIN-6 LEVELS WITH JOINT INVOLVEMENT AND THROMBOCYTOSIS IN SYSTEMIC JUVENILE RHEUMATOID-ARTHRITIS [J].

DEBENEDETTI, F ;

MASSA, M ;

ROBBIONI, P ;

RAVELLI, A ;

BURGIO, GR ;

MARTINI, A .

ARTHRITIS AND RHEUMATISM, 1991, 34 (09) :1158-1163

[6]

Donn RP, 2001, ARTHRITIS RHEUM, V44, P802, DOI 10.1002/1529-0131(200104)44:4<802::AID-ANR136>3.3.CO

[7]

2-7

[8] The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans [J].

Endler, G ;

Marsik, C ;

Joukhadar, C ;

Marculescu, R ;

Mayr, F ;

Mannhalter, C ;

Wagner, OF ;

Jilma, B .

CLINICAL CHEMISTRY, 2004, 50 (01) :195-200

[9] THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS [J].

FELSON, DT ;

ANDERSON, JJ ;

BOERS, M ;

BOMBARDIER, C ;

CHERNOFF, M ;

FRIED, B ;

FURST, D ;

GOLDSMITH, C ;

KIESZAK, S ;

LIGHTFOOT, R ;

PAULUS, H ;

TUGWELL, P ;

WEINBLATT, M ;

WIDMARK, R ;

WILLIAMS, HJ ;

WOLFE, F .

ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :729-740

[10] The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis [J].

Fishman, D ;

Faulds, G ;

Jeffery, R ;

Mohamed-Ali, V ;

Yudkin, JS ;

Humphries, S ;

Woo, P .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (07) :1369-1376

← 1 2 3 →